Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
/
Bioventus
Create a narrative
Bioventus Community
NasdaqGS:BVS Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Community Investing Ideas
Bioventus
Popular
Undervalued
Overvalued
Bioventus
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Minimally Invasive Nonopioid Pain Management Will Expand With PNS
Key Takeaways Launch of innovative pain management devices and strong growth across diverse product lines position the company for sustained revenue and margin expansion. Operational efficiencies combined with favorable market trends and payer support drive improved profitability and long-term growth momentum.
View narrative
US$12.75
FV
41.6% undervalued
intrinsic discount
5.07%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
11 days ago
author updated this narrative
Your Valuation for
BVS
BVS
Bioventus
Your Fair Value
US$
Current Price
US$7.44
33.8% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-170m
730m
2015
2018
2021
2024
2025
2027
2030
Revenue US$729.9m
Earnings US$2.4m
Advanced
Set Fair Value